Square Pharmaceuticals PLC reported a slight decline in third-quarter earnings, while nine-month profit and cash flow strengthened.
The largest drug maker of the country said in its disclosure that consolidated earnings per share (EPS) fell 1.46 per cent to Tk6.73 in January–March 2026, from Tk6.83 a year earlier.
For July 2025 to March 2026, consolidated EPS rose 10.12 per cent to Tk23.29 from Tk21.15 in the same period of the previous financial year.
Consolidated net operating cash flow per share increased 47.39 per cent to Tk17.54 for the nine-month period, compared with Tk11.90 a year earlier.
Consolidated net asset value per share rose 7.55 per cent to Tk169.79 on 31 March, from Tk157.88 at end of June last year.
Square Pharmaceuticals shares edged down 0.89 per cent to Tk211.80 on the Dhaka Stock Exchange on Thursday.
